Live Breaking News & Updates on Ulgaris

Stay informed with the latest breaking news from Ulgaris on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ulgaris and stay connected to the pulse of your community

HiST Pharma Announces U.S. FDA Approval to Initiate Phase III Clinical Study With TC Cream - World's First Botanical Small-Molecule Drug That Treats Psoriasis Vulgaris

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou (PRIG) announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND)

China , Guangzhou , Guangdong , Liping-yang , Jiangxi , Gewinn-nur , Drug-administration , National-medical-products-administration , Psoriasis-research-institute-of-guangzhou , Psoriasis-research-institute , Investigational-new-drug , Chief-physician

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, Dec. 17, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on

Stockholm , Sweden , Ola-holmlund , Erik-penser-bank , Menarini-group , Nasdaq-first-north , Global-data , Cadila-pharmaceutics , Lipidor , Xpands , Linical , Rogram

Lessons from Namyang fiasco

Lessons from Namyang fiasco
No company can survive without consumers' confidence
Namyang Dairy Products Chairman Hong Won-sik offered to resign Tuesday, apologizing for causing controversy over false claims about the anti-viral effects of the company's yogurt drink, Bulgaris. In a press conference at the company headquarters in southern Seoul, he also vowed not to hand over management of the company to his children.
Hong's resignation came three weeks after Namyang's research chief claimed in a symposium that Bulgaris reduces the chance of COVID-19 infections by 78 percent. Following the announcement, the company's shares soared and the yogurt drink sold out in many retail stores.

Seoul , Soult-ukpyolsi , South-korea , Namyang , Cholla-namdo , Ministry-of-food , Bulgari , Dairy-products-chairman-hong-won-sik , Drug-safety , Nti-viral-effect , Ogurt

The Latest: NKorea bows out of soccer matches, citing virus

The Latest: Germany eases some limits for those vaccinated
The Associated Press
FacebookTwitterEmail
36
1of36Harald Fischer gets a Moderna vaccination in a vaccination mobile on a square at the district Chorweiler in Cologne, Germany, Monday, May 3, 2021. The city of Cologne started a program to bring COVID-19 vaccination to people living in this neighborhood with a high corona incidence.Martin Meissner/APShow MoreShow Less
2of36FILE - In this April 27, 2021 file photo, European Commission President Ursula von der Leyen speaks during a debate on the EU-UK trade and cooperation agreement during the second day of a plenary session at the European Parliament in Brussels. The president of the European Union’s executive arm says a quarter of all EU residents have now received a first dose of coronavirus vaccine. “Vaccination is gaining speed across the EU: we have just passed 150 million vaccinations,” Ursula von der Leyen said in a message posted on Twitter. “(Olivier Hoslet, Pool via AP)Olivier Hoslet/APShow MoreShow Less

New-york , United-states , Pyongyang , P-yongyang-si , North-korea , Tokyo , Japan , Dubai , Dubayy , United-arab-emirates , Olympia , Washington

Angry investors call for Namyang boycott over pseudoscientific claims

Angry investors call for Namyang boycott over pseudoscientific claims
Posted : 2021-04-18 16:37
Updated : 2021-04-18 17:46
Namyang Dairy Products' Bulgaris drinking yogurt is on display at a supermarket in Seoul, last week. Yonhap
By Kim Jae-heun
Angry investors are calling on consumers to vote with their wallets by boycotting Namyang Dairy Products, after the company released the pseudoscientific claim that its yogurt drink Bulgaris can help control COVID-19.
After Namyang's claim, its share price rose over 8 percent, April 13, and by 28.68 percent the following morning. However, experts including those at the Korea Disease Control and Prevention Agency and the Ministry of Food and Drug Safety questioned Bulgaris' effectiveness against the coronavirus and concluded that the company had exaggerated "research" results. The dairy product firm's stock nosedived by nearly a third over the next four days.

Seoul , Soult-ukpyolsi , South-korea , Namyang , Cholla-namdo , Korea , Kim-jae-heun , Prevention-agency , Ministry-of-food , Bulgari , Namyang-dairy-product-bulgaris

Korea Exchange investigates Namyang over stock price irregularities

Food authorities accuse Namyang over irregularities
Posted : 2021-04-15 16:34
Updated : 2021-04-15 20:11
Korea Exchange investigates dairy firm over stock price irregularities
By Park Jae-hyuk
The Ministry of Food and Drug Safety accused Namyang Dairy Products of breaching the Act on Labeling and Advertising of Foods, Thursday, by announcing Bulgaris yogurt drinks were supposedly effective against COVID-19.
"Without animal experiments or clinical trials, Namyang announced Bulgaris was effective against COVID-19," the ministry said in a press release.
This came after the Korea Exchange (KRX) started an investigation into the dairy firm for alleged insider trading, following a momentary hike in its stock price which came following the announcement.

Namyang , Cholla-namdo , South-korea , Seoul , Soult-ukpyolsi , Korea , Financial-supervisory-service , Lw-convention-center , Korea-exchange , Namyang-dairy-product-bulgaris , Dairy-product-bulgaris